[go: up one dir, main page]

ATE426043T1 - Verfahren zur identifizierung des brustkrebsrisikos - Google Patents

Verfahren zur identifizierung des brustkrebsrisikos

Info

Publication number
ATE426043T1
ATE426043T1 AT03787201T AT03787201T ATE426043T1 AT E426043 T1 ATE426043 T1 AT E426043T1 AT 03787201 T AT03787201 T AT 03787201T AT 03787201 T AT03787201 T AT 03787201T AT E426043 T1 ATE426043 T1 AT E426043T1
Authority
AT
Austria
Prior art keywords
breast cancer
methods
cancer risk
subject
identifying
Prior art date
Application number
AT03787201T
Other languages
English (en)
Inventor
Richard Roth
Matthew Nelson
Andreas Braun
Stefan Kammerer
Rikard Reneland
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Application granted granted Critical
Publication of ATE426043T1 publication Critical patent/ATE426043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Peptides Or Proteins (AREA)
AT03787201T 2002-11-25 2003-11-25 Verfahren zur identifizierung des brustkrebsrisikos ATE426043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42913602P 2002-11-25 2002-11-25
US49023403P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
ATE426043T1 true ATE426043T1 (de) 2009-04-15

Family

ID=32397178

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03787201T ATE426043T1 (de) 2002-11-25 2003-11-25 Verfahren zur identifizierung des brustkrebsrisikos

Country Status (7)

Country Link
US (5) US20060204967A1 (de)
EP (2) EP1565582A4 (de)
AT (1) ATE426043T1 (de)
AU (4) AU2003298735A1 (de)
CA (2) CA2505784A1 (de)
DE (1) DE60326748D1 (de)
WO (4) WO2004047514A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
EP1565582A4 (de) 2002-11-25 2006-06-07 Sequenom Inc Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon
WO2004048546A2 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
WO2005118856A1 (en) * 2004-05-27 2005-12-15 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20070266003A1 (en) * 2006-05-09 2007-11-15 0752004 B.C. Ltd. Method and system for constructing dynamic and interacive family trees based upon an online social network
WO2008025093A1 (en) * 2006-09-01 2008-03-06 Innovative Dairy Products Pty Ltd Whole genome based genetic evaluation and selection process
US20080189047A1 (en) * 2006-11-01 2008-08-07 0752004 B.C. Ltd. Method and system for genetic research using genetic sampling via an interactive online network
EP2535425A1 (de) * 2007-05-25 2012-12-19 Decode Genetics EHF. Genetische varianten auf chr 10q26 als marker zur verwendung bei der risikobeurteilung, diagnose, prognose und behandlung von brustkrebs
US20090049856A1 (en) * 2007-08-20 2009-02-26 Honeywell International Inc. Working fluid of a blend of 1,1,1,3,3-pentafluoropane, 1,1,1,2,3,3-hexafluoropropane, and 1,1,1,2-tetrafluoroethane and method and apparatus for using
US20110311539A1 (en) * 2007-09-17 2011-12-22 Ludwig Institute For Cancer Research Ltd Diagnosis and treatment of cancer using cancer-testis antigens
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB2541463A (en) * 2015-08-21 2017-02-22 Univ Of Ha'il Novel methods
US10368846B2 (en) * 2016-06-29 2019-08-06 Niramai Health Analytix Pvt. Ltd. Classifying hormone receptor status of malignant tumorous tissue from breast thermographic images
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JPWO2018186032A1 (ja) * 2017-04-05 2020-02-13 国立大学法人千葉大学 Ｓｗｉ／ｓｎｆ複合体の機能阻害剤
CN111190393B (zh) * 2018-11-14 2021-07-23 长鑫存储技术有限公司 半导体制程自动化控制方法及装置
CN111383737A (zh) * 2018-12-28 2020-07-07 康多富国际有限公司 癌症保健食品组合确定方法及非瞬时计算机可读存储介质
US10851376B2 (en) * 2018-12-28 2020-12-01 The Florida International University Board Of Trustees Long noncoding RNAs in pulmonary airway inflammation
CN111383736A (zh) * 2018-12-28 2020-07-07 康多富国际有限公司 免疫系统疾病保健食品组合确定方法及其可读取储存媒体
WO2024148280A1 (en) 2023-01-06 2024-07-11 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928242T2 (de) 1988-07-08 1997-12-18 Chiron Corp Gap-gen-sequenzen und diagnoseverwendungen davon
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US6013431A (en) * 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
JPH08503362A (ja) * 1992-11-12 1996-04-16 メルク シヤープ エンド ドーム リミテツド ヒトＮＭＤＡ−Ｒ２Ａレセプターサブユニット及びヒトＮＭＤＡ−Ｒ１レセプターサブユニット同形体をコードするｃＤＮＡ、並びにそれを発現させるトランスフェクト細胞系
US6194144B1 (en) * 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
EP0679196B1 (de) * 1993-01-07 2004-05-26 Sequenom, Inc. Dns - sequenzierung durch massenspektronomie
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1995014108A1 (en) * 1993-11-17 1995-05-26 Amersham International Plc Primer extension mass spectroscopy nucleic acid sequencing method
US5869242A (en) * 1995-09-18 1999-02-09 Myriad Genetics, Inc. Mass spectrometry to assess DNA sequence polymorphisms
US5928906A (en) * 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6432668B1 (en) 1997-12-30 2002-08-13 Chiron Corporation Polynucleotides encoding human cyclin-dependent kinase (hPFTAIRE)
WO2001051666A1 (en) * 2000-01-12 2001-07-19 The General Hospital Corporation Methods for diagnosing and treating heart disease
AU2001288999A1 (en) * 2000-09-08 2002-03-22 Millennium Pharmaceuticals, Inc. 38646, a guanine nucleotide exchange factor and uses therefor
US20020155440A1 (en) * 2000-12-19 2002-10-24 Ljubimova Julia Y. Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
AU2002241821A1 (en) 2001-01-08 2002-07-16 Genomics Collaborative, Inc. Method of detecting polymorphisms associated with breast carcinoma in mhc genes
EP1565582A4 (de) 2002-11-25 2006-06-07 Sequenom Inc Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon
WO2004048546A2 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
AU2005314461B2 (en) 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
US8088587B2 (en) 2005-03-04 2012-01-03 Vanderbilt University Genetic variants increase the risk of age-related macular degeneration
AU2006220604A1 (en) 2005-03-07 2006-09-14 Board Of Regents, The University Of Texas System Diagnostic and therapeutic target for macular degeneration

Also Published As

Publication number Publication date
AU2003302732A8 (en) 2004-07-09
CA2505786C (en) 2011-06-21
US7510835B2 (en) 2009-03-31
WO2004047767A3 (en) 2005-04-14
US20050053958A1 (en) 2005-03-10
US20050214771A1 (en) 2005-09-29
WO2004047623A3 (en) 2004-10-14
EP1565579A4 (de) 2007-02-14
EP1565582A2 (de) 2005-08-24
US20090317816A1 (en) 2009-12-24
US20060204967A1 (en) 2006-09-14
EP1565579A2 (de) 2005-08-24
CA2505786A1 (en) 2004-06-10
WO2004047514A2 (en) 2004-06-10
AU2003293141A1 (en) 2004-06-18
WO2004055196A3 (en) 2005-02-24
AU2003302732A1 (en) 2004-07-09
DE60326748D1 (de) 2009-04-30
CA2505784A1 (en) 2004-06-10
AU2003298735A1 (en) 2004-06-18
AU2003295986A1 (en) 2004-06-18
WO2004055196A2 (en) 2004-07-01
WO2004047623A2 (en) 2004-06-10
EP1565582A4 (de) 2006-06-07
WO2004047767A2 (en) 2004-06-10
US20050192239A1 (en) 2005-09-01
AU2003293141A8 (en) 2004-06-18
WO2004047514A3 (en) 2004-11-04
EP1565579B1 (de) 2009-03-18

Similar Documents

Publication Publication Date Title
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE437962T1 (de) Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
EA200702203A1 (ru) Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2005059108A3 (en) Gene expression profiles and methods of use
DE602004015626D1 (de) Bei brustkrebs
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
ES2175095T3 (es) Marcadores de adn respecto al tamaño de una camada de cerdos.
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
ATE494390T1 (de) Verfahren und nukleinsäuren zur analyse von störungen der proliferation von kolonzellen
ATE449323T1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
DE60216416D1 (de) Verfahren zum nachweis von chloralhydrat in dichloressigsäure
WO2006063285A3 (en) Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
DE60218995D1 (de) Verfahren zur kit genotypierung von schweinen
EP2112229A3 (de) Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
DE60313366D1 (de) Nukleinsäuresonden und Verfahren zum Nachweis einer Zielnukleinsäuresequenz mit zwei oder mehr cis-Nukleinsäurebereichen
WO2006074061A3 (en) Methods for identifying risk of low bmd and treatments thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties